Hypermethylation and concurrent loss of TACSTD2 mRNA expression as a potential mark for epigenetic silencing has already been demonstrated for a number of human malignancies such as cholangiocarcinoma [35], lung adenocarcinoma [34], malignant glioma [43] and HCC [33]. This evidence concerns the gene TACSTD2 and malignant glioma.